Drospirenone/estetrol - Mithra Pharmaceuticals

Drug Profile

Drospirenone/estetrol - Mithra Pharmaceuticals

Alternative Names: DRSP/E4; E4/DRSP; Estelle; Estetrol/Drospirenone

Latest Information Update: 05 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Estetra S.A.
  • Class Androstenes; Antiandrogens; Gonadal steroid hormones; Oral contraceptives; Small molecules
  • Mechanism of Action Estrogen receptor beta modulators; Mineralocorticoid receptor antagonists; Progesterone receptor agonists; Testosterone congener inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Pregnancy

Most Recent Events

  • 05 Jul 2018 Estetra completes a phase II trial in Pregnancy (Prevention) in Netherlands, before July 2018 (PO) (EudraCT2016-004267-40)
  • 05 Jun 2018 Mithra signs a binding Heads of Terms agreement with Hyundai Pharm for marketing rights of drospirenone/estetrol in South Korea
  • 31 May 2018 Drospirenone/estetrol - Mithra Pharmaceuticals is available for future commercial licensing as of 31 May 2018. https://www.mithra.com/en/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top